Izutsu, Koji http://orcid.org/0000-0001-9129-8057
Kato, Hisashi
Sekiguchi, Naohiro
Fujisaki, Tomoaki
Kawakita, Toshiro
Obara, Naoshi
Matsue, Kosei
Nishimoto, Mitsutaka
Hatayama, Tomoyoshi
Inagaki, Mitsuo
Fujikawa, Ei
Funding for this research was provided by:
Janssen Pharmaceutical K.K., Tokyo, Japan
Article History
Received: 28 November 2023
Revised: 14 March 2024
Accepted: 18 March 2024
First Online: 10 April 2024
Declarations
:
: Koji Izutsu medical writing support for Janssen; payment to the institution as local investigator from MSD, AstraZeneca, AbbVie, Eisai, Incyte, Bristol Myers Squibb, Novartis, Pfizer, Jassen, Yakult, Kyowa Kirin, Ono pharmaceutical, Daiichi Sankyo; consultation fees/payment from Bristol Myers Squibb, AstraZeneca, Zenyaku, Kyowa Kirin, MSD, Nihon Shinyaku, AbbVie, Ono pharmaceuticals, Genmab, Mitsubishi Tanabe Pharma, Nihon Kayaku; received payment from Bristol Myers Squibb, AstraZeneca, Janssen, Eisai, Kyowa Kirin, Takeda, Chugai, Novartis, MSD, Symbio, Abbvie, Ono Pharmaceutical, Pfizer, Eli Lily, Daiichi Sankyo. Hisashi Kato received lecture fees from Janssen Pharmaceutical. Naohiro Sekiguchi received research funding from Janssen, Astellas, Ono, Incyte Biosciences Japan, Merck Sharp & Dohme, Otsuka, Pfizer. Kosei Matsue received research grant from ASZ. Mitsutaka Nishimoto received research funding from Janssen Pharma. Tomoaki Fujisaki, Toshiro Kawakita, and Naoshi Obara has nothing to disclose. Tomoyoshi Hatayama, Mitsuo Inagaki, and Ei Fujikawa are employees of Janssen Pharmaceutical K.K., Tokyo, Japan and holds stocks of Johnson & Johnson.